SLCO1B1 (Q9Y6L6) variants and mutations
SLCO1B1 (also known as Q9Y6L6) is a human protein-coding gene encoding a solute carrier organic anion transporter family member 1B1 protein. It mediates hepatic uptake of many organic anions and drugs from portal blood, strongly influencing their systemic clearance. Reduced-function variants can markedly increase exposure to certain statins, especially simvastatin, and raise the risk of statin-associated muscle toxicity. This analysis covers 1,248 SLCO1B1 variants and mutations. Of these, 93% have computational variant effect predictions. Disease context includes Rotor syndrome, response to statin, and Disorder of bilirubin metabolism and excretion. Example SLCO1B1 variants include M1?, D2E, and D2G.
Variant analysis overview
- Gene: SLCO1B1
- Protein: Q9Y6L6
- UniProt accession: Q9Y6L6
- Organism: Homo sapiens
- Variants analyzed: 1248
- Variant scope: all variants
- Completed: 2026-08-10
Variant and mutation evidence
- Variant composition: 1,001 unspecified-consequence records; 20 frameshift variants; 130 missense variants; 74 synonymous variants; 15 stop-gained variants; 3 in-frame deletions; 4 splice-region variants; 1 in-frame insertions
- Prediction scores: 1,164 variants have prediction scores (93% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Rotor syndrome, response to statin, Disorder of bilirubin metabolism and excretion, gout, Jaundice, bilirubin metabolism disease, Gilbert syndrome, Cholecystitis, ovarian dysfunction, response to simvastatin, diabetes mellitus, response to methotrexate.
Protein structure and variant hotspots
- Protein features: 12 transmembrane segments; 1 domains; 10 post-translational modification sites.
- Structural context: 558 variants have structural context.
- PTM context: 19 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable SLCO1B1 variants
Examples include M1?, D2E, D2G, D2N, D2V, D2Y, Q3*, Q3K. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1?, NCI-TCGA Cosmic COSV9991, Variant assessed as somatic; high impact.
- D2E (p.Asp2Glu), ExAC rs761348443, gnomAD rs761348443, REVEL 0.01, CADD 0.97
- D2G (p.Asp2Gly), TOPMed rs1466654490, gnomAD rs1466654490, REVEL 0.05, CADD 14.10
- D2N (p.Asp2Asn), TOPMed rs901600794, gnomAD rs901600794, REVEL 0.09, CADD 21.50
- D2V (p.Asp2Val), TOPMed rs1466654490, gnomAD rs1466654490, MetaLR 0.09, MetaSVM -1.00
- D2Y (p.Asp2Tyr), rs901600794, TOPMed rs901600794, gnomAD rs901600794, REVEL 0.10, CADD 23.30, Variant assessed as somatic; moderate impact.
- Q3* (p.Gln3Ter), TOPMed rs1174387858, gnomAD rs1174387858, Uncertain significance
- Q3K (p.Gln3Lys), TOPMed rs1174387858, gnomAD rs1174387858, REVEL 0.02, CADD 2.08, Uncertain significance, Cardiovascular phenotype
- N4I (p.Asn4Ile), gnomAD 12-21141581-CA-C, CADD 15.10
- N4D (p.Asn4Asp), gnomAD 12-21141584-A-G, REVEL 0.08, MetaLR 0.07
- Q5* (p.Gln5Ter), NCI-TCGA Cosmic COSV5700, Variant assessed as somatic; high impact.
- Q5Q (p.Gln5Gln), rs1940308950, gnomAD 12-21141589-A-G, CADD 0.11
- H6P (p.His6Pro), TOPMed rs1940308996, REVEL 0.04, CADD 5.96
- H6Y (p.His6Tyr), gnomAD 12-21141590-C-T, REVEL 0.06, MetaLR 0.12
- H6L (p.His6Leu), gnomAD 12-21141591-A-T, REVEL 0.08, MetaLR 0.13
- L7W (p.Leu7Trp), Ensembl rs1479021481
- L7F (p.Leu7Phe), gnomAD 12-21141595-G-C, REVEL 0.04, MetaLR 0.14
- N8D (p.Asn8Asp), NCI-TCGA TCGA novel, MetaLR 0.07, MetaSVM -1.01, Variant assessed as somatic; moderate impact.
- N8S (p.Asn8Ser), gnomAD 12-21141597-A-G, REVEL 0.04, MetaLR 0.08
- K9* (p.Lys9Ter), TOPMed rs1940309117
- K9R (p.Lys9Arg), gnomAD rs1940309182, REVEL 0.02, CADD 7.98
- K9T (p.Lys9Thr), gnomAD 12-21141600-A-C, REVEL 0.02, MetaLR 0.08
- T10A (p.Thr10Ala), Ensembl rs11557087, MetaLR 0.04, MetaSVM -1.03
- T10I (p.Thr10Ile), ExAC rs766950888, TOPMed rs766950888, gnomAD rs766950888, REVEL 0.02, CADD 9.31
- T10K (p.Thr10Lys), gnomAD 12-21141603-C-A, REVEL 0.04, MetaLR 0.08
- T10T (p.Thr10Thr), rs113635866, gnomAD 12-21141604-A-G, CADD 1.02
- A11S (p.Ala11Ser), rs1940309529, ClinGen CA384101143, ClinVar RCV004305955, Ensembl rs1940309529, REVEL 0.01, CADD 0.24, Uncertain significance, Cardiovascular phenotype
- A11V (p.Ala11Val), rs2498109273, ClinGen CA384101148, ClinVar RCV004280487, REVEL 0.05, CADD 11.00, Uncertain significance, Cardiovascular phenotype
- A11T (p.Ala11Thr), gnomAD 12-21141605-G-A, REVEL 0.01, MetaLR 0.05
- A11A (p.Ala11Ala), gnomAD 12-21141607-A-G, CADD 6.06
- E12* (p.Glu12Ter), ExAC rs756064979, TOPMed rs756064979, gnomAD rs756064979, CADD 34.00
- E12K (p.Glu12Lys), ExAC rs756064979, TOPMed rs756064979, gnomAD rs756064979, REVEL 0.02, CADD 13.00
- E12Q (p.Glu12Gln), NCI-TCGA Cosmic COSV5701, MetaLR 0.09, MetaSVM -1.03, Variant assessed as somatic; moderate impact.
- E12R (p.Glu12Arg), gnomAD 12-21141606-CA-C, CADD 19.80
- A13E (p.Ala13Glu), ExAC rs778214174, TOPMed rs778214174, gnomAD rs778214174, REVEL 0.07, CADD 0.22
- A13V (p.Ala13Val), gnomAD 12-21141612-C-T, REVEL 0.06, MetaLR 0.10
- Q14* (p.Gln14Ter), TOPMed rs1239843192
- Q14K (p.Gln14Lys), NCI-TCGA Cosmic COSV9991, MetaLR 0.09, MetaSVM -0.98, Variant assessed as somatic; moderate impact.
- Q14Q (p.Gln14Gln), gnomAD 12-21141616-A-G, CADD 0.40
- P15S (p.Pro15Ser), TOPMed rs1940309779, gnomAD rs1940309779, REVEL 0.03, CADD 0.00
- P15T (p.Pro15Thr), gnomAD 12-21141617-C-A, REVEL 0.04, MetaLR 0.17
- P15R (p.Pro15Arg), gnomAD 12-21141618-C-G, REVEL 0.04, MetaLR 0.14
- S16L (p.Ser16Leu), ExAC rs753618172, gnomAD rs753618172, REVEL 0.04, CADD 13.70
- S16* (p.Ser16Ter), gnomAD 12-21141621-C-G, CADD 33.00
- S16S (p.Ser16Ser), gnomAD 12-21141622-A-G, CADD 1.01
- E17A (p.Glu17Ala), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- E17K (p.Glu17Lys), TOPMed rs1940309915, MetaLR 0.10, MetaSVM -1.00, Uncertain significance, Cardiovascular phenotype
- E17* (p.Glu17Ter), gnomAD 12-21141623-G-T, CADD 26.80
- E17V (p.Glu17Val), gnomAD 12-21141624-A-T, REVEL 0.08, MetaLR 0.15
- E17E (p.Glu17Glu), rs754752027, gnomAD 12-21141625-G-A, CADD 1.43
- N18del (p.Asn18del), rs1565664071, gnomAD 12-21141625-GAAT-, CADD 7.20
- N18S (p.Asn18Ser), gnomAD 12-21141627-A-G, REVEL 0.07, MetaLR 0.06
- K19* (p.Lys19Ter), ESP rs376829525, ExAC rs376829525, TOPMed rs376829525, gnomAD rs376829525, CADD 33.00
- K19E (p.Lys19Glu), gnomAD 12-21141629-A-G, REVEL 0.06, MetaLR 0.08
- K20E (p.Lys20Glu), rs1261110525, TOPMed rs1261110525, MutPred 0.43, Variant assessed as somatic; moderate impact.
- K20N (p.Lys20Asn), NCI-TCGA Cosmic COSV9991, MetaLR 0.17, MetaSVM -0.94, Variant assessed as somatic; moderate impact.
- K20T (p.Lys20Thr), ExAC rs748310464, gnomAD rs748310464, REVEL 0.05, CADD 15.30
- T21I (p.Thr21Ile), Ensembl rs1591796264, MetaLR 0.14, MetaSVM -0.98
- T21Q (p.Thr21Gln), rs755776876, gnomAD 12-21141630-AG-A, CADD 17.30
- R22S (p.Arg22Ser), rs142087529, ClinGen CA6476546, ClinVar RCV000284110, ESP rs142087529, REVEL 0.15, CADD 10.80, Uncertain significance, Rotor syndrome
- R22T (p.Arg22Thr), rs758561937, ClinGen CA6476545, NCI-TCGA Cosmic COSV5700, ClinVar RCV004350429, REVEL 0.14, CADD 5.24, Uncertain significance, Cardiovascular phenotype
- R22R (p.Arg22Arg), rs1370952132, gnomAD 12-21141638-A-C, CADD 4.03
- R22G (p.Arg22Gly), gnomAD 12-21141638-A-G, REVEL 0.23, MetaLR 0.17
- R22I (p.Arg22Ile), gnomAD 12-21141639-G-T, REVEL 0.21, MetaLR 0.17
- Y23F (p.Tyr23Phe), gnomAD rs1238688577, REVEL 0.15, CADD 0.03
- Y23H (p.Tyr23His), TOPMed rs1005797496, gnomAD rs1005797496, REVEL 0.09, CADD 0.73
- Y23N (p.Tyr23Asn), TOPMed rs1005797496, gnomAD rs1005797496, MetaLR 0.08, MetaSVM -1.06
- Y23* (p.Tyr23Ter), gnomAD 12-21141642-ACT-A, CADD 26.30
- Y23Y (p.Tyr23Tyr), rs747107414, gnomAD 12-21141643-C-T, CADD 0.41
- C24F (p.Cys24Phe), rs771380189, NCI-TCGA Cosmic COSV5701, ExAC rs771380189, gnomAD rs771380189, REVEL 0.26, CADD 21.60, Variant assessed as somatic; moderate impact.
- C24S (p.Cys24Ser), gnomAD rs1348207461, REVEL 0.22, CADD 21.50
- C24Y (p.Cys24Tyr), ExAC rs771380189, gnomAD rs771380189, REVEL 0.32, CADD 22.60
- C24R (p.Cys24Arg), gnomAD 12-21141644-T-C, REVEL 0.24, MetaLR 0.27
- C24* (p.Cys24Ter), gnomAD 12-21141646-C-A, CADD 31.00
- N25S (p.Asn25Ser), TOPMed rs1236489495, REVEL 0.06, CADD 13.80
- N25T (p.Asn25Thr), gnomAD 12-21141648-A-C, REVEL 0.03, MetaLR 0.12
- N25N (p.Asn25Asn), rs1337146914, gnomAD 12-21141649-T-C, CADD 5.57
- G26* (p.Gly26Ter), NCI-TCGA TCGA novel, CADD 36.00, Variant assessed as somatic; high impact.
- G26R (p.Gly26Arg), Ensembl rs867256020, REVEL 0.17, CADD 22.50
- G26A (p.Gly26Ala), gnomAD 12-21141651-G-C, REVEL 0.14, MetaLR 0.17
- L27S (p.Leu27Ser), Ensembl rs1591796292, REVEL 0.32, CADD 23.90
- L27L (p.Leu27Leu), rs190581845, gnomAD 12-21141653-T-C, CADD 5.44
- K28M (p.Lys28Met), Ensembl rs1940310881
- K28N (p.Lys28Asn), NCI-TCGA TCGA novel, MetaLR 0.38, MetaSVM -0.16, Variant assessed as somatic; moderate impact.
- K28* (p.Lys28Ter), gnomAD 12-21141656-A-T, CADD 48.00
- K28E (p.Lys28Glu), gnomAD 12-21141656-A-G, REVEL 0.37, MetaLR 0.34
- K28R (p.Lys28Arg), gnomAD 12-21141657-A-G, REVEL 0.14, MetaLR 0.16
- M29K (p.Met29Lys), ExAC rs762818214, gnomAD rs762818214, REVEL 0.34, CADD 28.20
- M29V (p.Met29Val), ESP rs146317972, TOPMed rs146317972, MetaLR 0.07, MetaSVM -1.06
- M29L (p.Met29Leu), gnomAD 12-21172650-A-C, REVEL 0.03, MetaLR 0.07
- F30L (p.Phe30Leu), NCI-TCGA TCGA novel, REVEL 0.35, CADD 17.70, Variant assessed as somatic; moderate impact.
- F30I (p.Phe30Ile), gnomAD 12-21172653-T-A, REVEL 0.61, MetaLR 0.32
- L31S (p.Leu31Ser), NCI-TCGA TCGA novel, MetaLR 0.22, MetaSVM -0.84, Variant assessed as somatic; moderate impact.
- L31L (p.Leu31Leu), gnomAD 12-21172656-T-C, CADD 2.28
- L31F (p.Leu31Phe), gnomAD 12-21172658-G-T, REVEL 0.09, MetaLR 0.17
- A32E (p.Ala32Glu), TOPMed rs918985116, gnomAD rs918985116, REVEL 0.18, CADD 14.00
- A32T (p.Ala32Thr), Ensembl rs1940769670, MetaLR 0.12, MetaSVM -0.97
- A32V (p.Ala32Val), TOPMed rs918985116, gnomAD rs918985116, REVEL 0.04, CADD 3.39
- A33H (p.Ala33His), gnomAD 12-21172660-CAGCT, CADD 25.70
- A33T (p.Ala33Thr), gnomAD 12-21172662-G-A, REVEL 0.31, MetaLR 0.29
- L34M (p.Leu34Met), NCI-TCGA TCGA novel, MetaLR 0.38, MetaSVM -0.30, Variant assessed as somatic; moderate impact.
- L34P (p.Leu34Pro), TOPMed rs929681002, gnomAD rs929681002, REVEL 0.65, CADD 24.90
- L34V (p.Leu34Val), ExAC rs764431918, TOPMed rs764431918, gnomAD rs764431918, REVEL 0.38, CADD 19.70
- L34L (p.Leu34Leu), gnomAD 12-21172667-G-T, CADD 2.22
- S35* (p.Ser35Ter), gnomAD 12-21172669-C-A, CADD 35.00
- L36F (p.Leu36Phe), ExAC rs751767004, TOPMed rs751767004, gnomAD rs751767004, REVEL 0.17, CADD 0.01
- L36A (p.Leu36Ala), gnomAD 12-21172670-A-AG, CADD 16.10
- S37R (p.Ser37Arg), NCI-TCGA Cosmic COSV5701, 1000Genomes rs1349344368, gnomAD rs1349344368, MetaLR 0.30, MetaSVM -0.49, Variant assessed as somatic; moderate impact.
- S37T (p.Ser37Thr), 1000Genomes rs556524705, ExAC rs556524705, TOPMed rs556524705, gnomAD rs556524705, REVEL 0.15, CADD 4.25, Uncertain significance, Cardiovascular phenotype
- S37S (p.Ser37Ser), rs1349344368, gnomAD 12-21172676-C-T, CADD 6.21
- F38L (p.Phe38Leu), NCI-TCGA Cosmic COSV9991, MetaLR 0.20, MetaSVM -0.80, Variant assessed as somatic; moderate impact.
- I39M (p.Ile39Met), gnomAD rs1322023824, REVEL 0.11, CADD 7.64
- I39N (p.Ile39Asn), ESP rs370556411, ExAC rs370556411, TOPMed rs370556411, gnomAD rs370556411, REVEL 0.33, CADD 23.00
- I39T (p.Ile39Thr), ESP rs370556411, ExAC rs370556411, TOPMed rs370556411, gnomAD rs370556411, MetaLR 0.30, MetaSVM -0.34
- I39I (p.Ile39Ile), gnomAD 12-21172682-T-C, CADD 3.77
- A40T (p.Ala40Thr), ExAC rs750457469, TOPMed rs750457469, gnomAD rs750457469, REVEL 0.12, CADD 13.40
- A40A (p.Ala40Ala), rs896075819, gnomAD 12-21172685-T-C, CADD 4.35
- K41E (p.Lys41Glu), gnomAD 12-21172686-A-G, REVEL 0.35, MetaLR 0.28
- K41K (p.Lys41Lys), rs756685161, gnomAD 12-21172688-G-A, CADD 0.89
- T42I (p.Thr42Ile), 1000Genomes rs576786579, ExAC rs576786579, gnomAD rs576786579, REVEL 0.15, CADD 13.90
- T42P (p.Thr42Pro), rs780511571, ClinGen CA6476590, ClinVar RCV001111311, ExAC rs780511571, REVEL 0.18, CADD 7.96, Uncertain significance, Rotor syndrome
- T42K (p.Thr42Lys), gnomAD 12-21172690-C-A, REVEL 0.17, MetaLR 0.21
- T42T (p.Thr42Thr), rs542572546, gnomAD 12-21172691-A-G, CADD 2.22
- L43I (p.Leu43Ile), rs746610546, ClinGen CA384103621, ClinVar RCV004457116, ExAC rs746610546, REVEL 0.07, CADD 11.60, Uncertain significance, Cardiovascular phenotype
- L43P (p.Leu43Pro), ExAC rs770472561, TOPMed rs770472561, gnomAD rs770472561, REVEL 0.35, CADD 24.10
- L43V (p.Leu43Val), ExAC rs746610546, TOPMed rs746610546, gnomAD rs746610546, REVEL 0.06, CADD 15.90, Uncertain significance
- G44R (p.Gly44Arg), TOPMed rs1247637793, gnomAD rs1247637793, REVEL 0.21, CADD 17.00
- G44V (p.Gly44Val), gnomAD 12-21172694-AG-A, CADD 16.70
- G44G (p.Gly44Gly), rs1342777436, gnomAD 12-21172697-T-G, CADD 5.69
- A45T (p.Ala45Thr), rs555367334, NCI-TCGA Cosmic COSV5700, NCI-TCGA Cosmic COSV5701, 1000Genomes rs555367334, REVEL 0.17, CADD 21.50, Variant assessed as somatic; moderate impact.
- A45A (p.Ala45Ala), gnomAD 12-21172700-A-G, CADD 2.85
- I46N (p.Ile46Asn), NCI-TCGA TCGA novel, MetaLR 0.16, MetaSVM -0.90, Variant assessed as somatic; moderate impact.
- I46L (p.Ile46Leu), gnomAD 12-21172699-CA-C, CADD 16.90
- I46V (p.Ile46Val), gnomAD 12-21172701-A-G, REVEL 0.03, MetaLR 0.06
- I47del (p.Ile47del), gnomAD 12-21172700-AATT-, CADD 3.43
- M48I (p.Met48Ile), NCI-TCGA Cosmic COSV5701, REVEL 0.21, CADD 24.60, Variant assessed as somatic; moderate impact.
- M48R (p.Met48Arg), TOPMed rs1233372012, gnomAD rs1233372012, REVEL 0.57, CADD 25.10
- K49E (p.Lys49Glu), ExAC rs745339838, gnomAD rs745339838, REVEL 0.42, CADD 25.20
- S51F (p.Ser51Phe), rs769900186, ClinGen CA6476598, ClinVar RCV003643512, ExAC rs769900186, REVEL 0.37, CADD 22.60, Uncertain significance, Rotor syndrome
- S51Y (p.Ser51Tyr), NCI-TCGA Cosmic COSV5700, NCI-TCGA Cosmic COSV5701, Variant assessed as somatic; moderate impact.
- S51S (p.Ser51Ser), rs775517998, gnomAD 12-21172718-C-A, CADD 6.75
- I52F (p.Ile52Phe), ExAC rs762874802, TOPMed rs762874802, gnomAD rs762874802, REVEL 0.30, CADD 21.90
- I52T (p.Ile52Thr), Ensembl rs937855856, REVEL 0.30, CADD 19.70
- I52V (p.Ile52Val), ExAC rs762874802, TOPMed rs762874802, gnomAD rs762874802, REVEL 0.19, CADD 16.00
- I53V (p.Ile53Val), gnomAD 12-21172722-A-G, REVEL 0.15, MetaLR 0.06
- H54L (p.His54Leu), TOPMed rs1053682878
- H54R (p.His54Arg), TOPMed rs1053682878, MetaLR 0.05, MetaSVM -0.99
- H54E (p.His54Glu), gnomAD 12-21172724-TCATA, CADD 31.00
- H54H (p.His54His), gnomAD 12-21172727-T-C, CADD 1.10
- I55K (p.Ile55Lys), ExAC rs774451034, TOPMed rs774451034, gnomAD rs774451034, REVEL 0.72, CADD 26.00
- I55L (p.Ile55Leu), TOPMed rs915159194, gnomAD rs915159194, REVEL 0.18, CADD 24.30
- I55M (p.Ile55Met), NCI-TCGA TCGA novel, MetaLR 0.31, MetaSVM -0.57, Variant assessed as somatic; moderate impact.
- I55V (p.Ile55Val), TOPMed rs915159194, gnomAD rs915159194, REVEL 0.25, CADD 23.80
- E56D (p.Glu56Asp), ExAC rs762153831, gnomAD rs762153831, REVEL 0.68, CADD 24.30
- E56K (p.Glu56Lys), TOPMed rs1940770972, MetaLR 0.64, MetaSVM 0.57
- E56E (p.Glu56Glu), gnomAD 12-21172733-A-G, CADD 10.20
- R57Q (p.Arg57Gln), rs61760182, ClinGen CA6476605, ClinVar RCV001111313, 1000Genomes rs61760182, REVEL 0.41, CADD 27.70, Uncertain significance, Rotor syndrome
- R57W (p.Arg57Trp), rs139257324, ClinGen CA6476604, ClinVar RCV001111312, ESP rs139257324, REVEL 0.57, CADD 25.40, Uncertain significance, Rotor syndrome
- R57L (p.Arg57Leu), gnomAD 12-21172735-G-T, REVEL 0.61, MetaLR 0.39
- R58I (p.Arg58Ile), TOPMed rs891798349, gnomAD rs891798349, REVEL 0.72, CADD 26.90
- R58K (p.Arg58Lys), TOPMed rs891798349, gnomAD rs891798349
- F59C (p.Phe59Cys), TOPMed rs1940771354, gnomAD rs1940771354, REVEL 0.77, CADD 29.20
- F59L (p.Phe59Leu), ExAC rs756167965, gnomAD rs756167965, REVEL 0.70, CADD 28.10
- E60D (p.Glu60Asp), NCI-TCGA Cosmic COSV5701, Variant assessed as somatic; moderate impact.
- E60K (p.Glu60Lys), TOPMed rs1940771410
- E60Q (p.Glu60Gln), NCI-TCGA TCGA novel, MetaLR 0.22, MetaSVM -0.42, Variant assessed as somatic; moderate impact.
- E60E (p.Glu60Glu), rs1010243097, gnomAD 12-21172745-G-A, CADD 4.58
- I61L (p.Ile61Leu), gnomAD 12-21172746-A-T, REVEL 0.05, MetaLR 0.08
- I61T (p.Ile61Thr), gnomAD 12-21172747-T-C, REVEL 0.29, MetaLR 0.21
- S62A (p.Ser62Ala), ESP rs144164853, TOPMed rs144164853, gnomAD rs144164853, REVEL 0.14, CADD 14.10, Uncertain significance
- S62F (p.Ser62Phe), NCI-TCGA Cosmic COSV5700, REVEL 0.33, CADD 25.60, Variant assessed as somatic; moderate impact.
- S62P (p.Ser62Pro), rs144164853, ClinGen CA10632399, ClinVar RCV000339101, ESP rs144164853, REVEL 0.08, CADD 7.23, Uncertain significance, Rotor syndrome
- S62T (p.Ser62Thr), ESP rs144164853, TOPMed rs144164853, gnomAD rs144164853, Uncertain significance
- S62Y (p.Ser62Tyr), NCI-TCGA Cosmic COSV5700, Variant assessed as somatic; moderate impact.
- S62S (p.Ser62Ser), gnomAD 12-21172751-C-T, CADD 6.80
- S63P (p.Ser63Pro), Ensembl rs1565672584, REVEL 0.40, CADD 25.90
- S63T (p.Ser63Thr), gnomAD 12-21172752-T-A, REVEL 0.27, MetaLR 0.16
- S63F (p.Ser63Phe), gnomAD 12-21172753-C-T, REVEL 0.50, MetaLR 0.44
- S64C (p.Ser64Cys), gnomAD rs1479599092, REVEL 0.29, CADD 25.40
- S64Y (p.Ser64Tyr), gnomAD rs1479599092, REVEL 0.20, CADD 25.30
Public SLCO1B1 analysis runs
- SLCO1B1 analysis run — SLCO1B1 (1,248 variants) — completed 2026-08-10